Logo

Kristiina Vuori

Jun 12, 2019

Bionano Genomics has appointed Kristiina Vuori to its board of directors. Vuori is president and a board member of the Sanford Burnham Prebys Medical Discovery Institute (SBP.) She also serves as a professor at SBP's National Cancer Institute-designated Cancer Center. She holds an MD and PhD from Finland's University of Oulu. Her research has helped delineate molecular pathways that regulate cancer cell survival, motility, metastasis, and drug responsiveness. Her molecular characterization of prolyl hydroxylase helped to enable the formation of FibroGen. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.